CHOVANCOVÁ, Zita, Marcela VLKOVÁ, Jiří LITZMAN, Jindřich LOKAJ and Vojtěch THON. Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination. Vaccine. 2011, vol. 29, No 24, p. 4142–4150. ISSN 0264-410X. doi:10.1016/j.vaccine.2011.03.087.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination
Authors CHOVANCOVÁ, Zita (203 Czech Republic, belonging to the institution), Marcela VLKOVÁ (203 Czech Republic, belonging to the institution), Jiří LITZMAN (203 Czech Republic, belonging to the institution), Jindřich LOKAJ (203 Czech Republic, belonging to the institution) and Vojtěch THON (203 Czech Republic, guarantor, belonging to the institution).
Edition Vaccine, 2011, 0264-410X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.766
RIV identification code RIV/00216224:14110/11:00059060
Organization unit Faculty of Medicine
UT WoS 000292176800010
Keywords in English CVID Tetanus toxoid Pneumococcal vaccine ELISPOT
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 21/4/2013 11:40.
Common variable immunodeficiency (CVID), the most frequent primary antibody disorder, is characterized by hypogammaglobulinaemia and impaired antibody production. Poor vaccination response is essential for the diagnosis of CVID. Their under laying defects remain to be elucidated. Routine determination of antibody production in serum from CVID patients after vaccination and investigation of B cell function in vivo is complicated due to substitution therapy. Therefore we investigated antibody production on the B-cell level by ELISPOT and characterized changes in B-cell subpopulations in CVID patients, including plasmablasts, in peripheral blood by flow cytometry after vaccination for specification of the diagnosis. Thirty-seven CVID patients and eighty healthy volunteers were immunized with tetanus toxoid and pneumococcal polysaccharide vaccines. Specific antibody levels and B cell subpopulations were measured before vaccination and on day 7 after vaccination by ELISPOT assay and flow cytometry respectively. Of the thirty-seven well defined CVID patients studied, thirty lacked detectable spot forming cells producing specific IgG, IgA or IgM antibodies against employed vaccines and seven had only weak responses compared to controls. In the control group, an increase in circulating plasmablasts on day 7 post immunization corresponded with the appearance of antibody forming cells. In contrast, CVID patients failed to increase plasmablasts significantly in peripheral blood after antigen challenge. Our findings indicate that CVID patients have a block in terminal B-cell differentiation and that flow based assessment of plasmablasts in peripheral blood after vaccination serves as a surrogate diagnostic marker for assessing in vivo antibody responses in patients suspected to have CVID.
7E08062, research and development projectName: Pathophysiology and Natural Course of Primary Antibody Deficiency (PAD) Syndromes
Investor: Ministry of Education, Youth and Sports of the CR, Subvention of the projects of the Seventh Framework Programme of the European Community for research, technological development including demonstration activities (2007-2013)
PrintDisplayed: 23/4/2021 07:26